Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

23-24 September 2016

Amsterdam, The Netherlands

Scientific Agenda

Friday, September 11, 2015

8:00

Welcome address and day one overview
John M. Kirkwood, MD, Antoni Ribas, MD, PhD

Session I: Melanoma Epidemiology, Genetics, Staging and Prognostication

8:05 am

Pre-session audience response survey

8:10 am

Genomic sequencing and mutations in melanoma
Michael A. Davies, MD, PhD

8:30 am

Implications of genomic information on melanoma staging
Speaker invited

8:50 am

Melanoma phenotypic characterization and phenotype switching
Speaker invited

9:10 am

Post-session audience response survey

9:15 am

Q&A

9:25 am

Break

Session II: Melanoma Screening

9:45 am

Pre-session audience response survey

9:50 am

Melanoma surveillance and early detection
Laura Ferris, MD, PhD

10:10 am

Topic to be determined

10:30 am

Post-session audience response survey

10:35 am

Q & A

Session III: Oral Abstract Session I

10:40 am

Presentation of selected abstracts

11:40 am

Lunch

Session IV: Oral Abstract Session II

1:00 pm

Presentation of selected abstracts

Session V: Genetics of Melanoma Immunotherapy

2:00 pm

Pre-session audience response survey

2:05 pm

Analysis of the mutational burden in melanoma and the efficacy of immunotherapy
Speaker invited

2:25 pm

The role of CD8 and CD4 T cell response to melanoma antigens
John B.A.G. Haanen, MD, PhD

2:45 pm

MicoRNAs in melanoma
Speaker invited

3:05 pm

Post-session audience response survey

3:10 pm

Q&A

3:20 pm

Coffee Break

Session VI: Biology of Immune Checkpoint Inhibition

3:40 pm

Pre-session Audience Response Survey

3:45 pm

Inflammation and T cell exclusion in melanoma
Thomas F. Gajewski, MD, PhD

4:05 pm

Radiation therapy combined with checkpoint inhibition
Tara Gangadhar, MD

4:25 pm

Post-session audience response survey

4:30 pm

Q&A

4:40 pm

Closing remarks
John M. Kirkwood, MD and Antoni Ribas, MD, PhD

4:45 pm

Adjourn

Saturday, September 12, 2015

8:30 am

Day two overview
John M. Kirkwood, MD and Antoni Ribas, MD, PhD

Session VII: Biology of BRAF and MEK Inhibition

8:05 am

Pre-session audience response survey

8:10 am

Melanoma adaptation to BRAF and MEK inhibitors and acquired resistance
Roger Lo, MD, PhD

8:30 am

Rationale for the clinical testing of intermittent BRAF and MEK inhibitor therapy
Speaker invited

8:50 am

Continuing advances in using BRAF inhibitors with other targeted therapies
Speaker invited

9:10 am

Post-session audience response survey

9:15 am

Q&A

9:30 am

Break

Session VIII: Immunotherapy for Melanoma

10:00 am

Pre-session audience response survey

10:05 am

Immunotherapy with anti-PD-1 and anti-PD-L1 inhibition
Speaker invited

10:25 am

Beyond CTLA4 and PD1: New approaches to enhance immunotherapy of cancer with novel checkpoint inhibitor combinations
Hassane M. Zarour, MD

10:45 am

Adoptive cell transfer therapy for melanoma
John B.A.G. Haanen, MD, PhD

11:05 am

Rationale for and the clinical testing of combination therapy with PD-1 blockade in melanoma
Michael Postow, MD

11:25 pm

Post-session audience response survey

11:30 pm

Q & A

11:45 pm

Lunch

Session IX: Next Developments in Therapy of Melanoma

Moderator: Antoni Ribas, MD, PhD

1:15 pm

Pre-session audience response survey

1:20 pm

Rationale for comparing combination immunotherapy and targeted therapy in the intergroup EA6134 trial for metastatic V600E melanoma
Speaker invited

1:40 pm

Surgical controversies in melanoma (panel discussion)

2:00 pm

Soluble TCR therapy for melanoma
Speaker invited

2:20 pm

Post-session audience response survey

2:25 pm

Q & A

2:40 pm

Break

Session X: Adjuvant and Neoadjuvant Therapy and Biomarkers in Melanoma

3:00 pm

Pre-session audience response survey

3:05 pm

Role of Immunotherapy for locoregional and early metastatic melanoma
Speaker invited

3:25 pm

What is new in adjuvant and neoadjuvant therapy for melanoma
John M. Kirkwood, MD

3:45 pm

Rationale and design of Intergroup S1404 trial of pembrolizumab versus high-dose interferon
Kenneth F. Grossman, MD, PhD

4:05 pm

Biomarkers of adjuvant melanoma therapy: From interferons and anti-CTLA4 to anti-PD1 and new combinations
Ahmad Tarhini, MD

4:25 pm

Post-session audience response survey

4:30 pm

Q & A

4:40 pm

Closing remarks
John M. Kirkwood, MD and Antoni Ribas, MD, PhD

4:45 pm

Adjourn